HempNewsBreaks

TuesdayOct 19, 2021 2:49 pm

HempNewsBreaks – BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE:7BC) Bringing Leading US Beverage Brands to Canadian Market

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health and wellness beverage and natural products company, is developing and manufacturing a range of alkaline, plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. The company has sought to capitalize on the growing demand, most recently through its various collaborations with U.S. cannabis-infused beverage manufacturers. Strong growth trends of the cannabis-derived drinks market in the U.S. look promising for the nascent Canadian sector, which is poised for significant growth in the coming months and years. “A key driver set to underpin future growth within the…

Continue Reading

WednesdayOct 13, 2021 3:01 pm

HempNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Expands Footprint, GMP Certifications to Three

Flora Growth (NASDAQ: FLGC) is currently seeking revenue-generating acquisitions and strategic partnerships that offer a larger distribution network, amplify revenue growth and complement its human capital. “In recent months, Flora has announced three major transactions — Vessel Brand, Koch & Gsell, and Hoshi International,” reads a recent article. The acquisition of Vessel Brand is expected to expand Flora’s premium brand and product portfolio while diversifying its global distribution channels. The acquisition of Koch & Gsell, which is expected to introduce Flora Growth’s products to the Swiss, European and Asian markets, promises to bring patented hemp cigarette manufacturing technology into new…

Continue Reading

WednesdayOct 13, 2021 2:39 pm

HempNewsBreaks – BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE:7BC) Leveraging State-of-the-Art Facilities, Expertise in Rapidly Growing Market

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health and wellness beverage and natural products company, is in a position to leverage its state-of-the-art facilities and expertise to manufacture its own beverage product lines and to provide white-label solutions to a growing list of third-party companies. This comes as a recent Expert Market Research (“EMR”) report projects that North America is likely to be the fastest-growing and largest marketplace for cannabis beverages and that the global market will grow at a 48% CAGR in the next five years. Thus, BevCanna is ideally situated. A recent article reads, “The…

Continue Reading

FridayOct 08, 2021 11:38 am

HempNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Poised to Become Global Leader in Manufacture of Rare Cannabinoids

InMed Pharmaceuticals (NASDAQ: INM) recently announced it had signed a definitive agreement to acquire 100% of BayMedica Inc., a U.S.-based private company specializing in the manufacture and commercialization of rare cannabinoids. InMed CEO Eric A. Adams described the acquisition as a transformative transaction for the company as it would give InMed a breadth of synthetic cannabinoid manufacturing capabilities. “BayMedica brings unparalleled cannabinoid manufacturing expertise in both chemical synthesis and biosynthesis together with industry veterans who have been pioneers in this space,” a recent article quotes Adams as saying. The article further notes that, once closed, the transaction will create a…

Continue Reading

WednesdayOct 06, 2021 1:57 pm

HempNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Achieves 13% QOQ Revenue Growth, Marks Remarkable Q2 2021

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) recently released its financial results for the second quarter of fiscal 2021. The company’s revenue was up 13% to $13.3 million, from $11.8 million in Q1 2021. In addition to a growth in revenue, RWB also received the Florida Department of Health, Office of Medical Marijuana Use approval; closed the acquisition of Acreage Florida; secured 20 double wide fully enclosed cultivation pods that will offer approximately 19,000 square feet of turn-key cultivation space; and completed the more comprehensive portion of Michigan’s two-step application process for medical marijuana licensing through its wholly…

Continue Reading

TuesdayOct 05, 2021 2:53 pm

HempNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Releases Preliminary Results Showing HyGrO Technology Could Increase Longevity of Cut Flowers

Golden Triangle Ventures (OTC: GTVH) released the successful results of preliminary testing of its proprietary HyGrO hydrogen water technology and is looking forward to pursuing larger-scale studies. The company will work with commercial-scale flower products to further evaluate the efficacy of GTVH’s new process. The preliminary research, which lasted 21 days, was designed to assess whether hydrogen-infused water via the HyFrontier Technologies HyGrO system would increase the longevity of cut flowers, including stock roses, carnations and gladiolas. “Two vases were filled, one with regular tap water and one with HyGrO water. The water was never changed, and pictures were taken…

Continue Reading

WednesdaySep 29, 2021 1:35 pm

HempNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Improved Delivery for Wide Range of Product Formats

Lexaria Bioscience Corp. (NASDAQ: LEXX), an innovator of drug delivery methods, is improving the speed and efficiency of orally delivered fat-soluble active molecules and drugs with its patented technology. “DehydraTECH promotes a more effective, less expensive form of oral drug delivery evaluated thoroughly in vivo, in vitro and human clinical testing,” reads a recent article. “The DehydraTECH technology is suitable for use with a wide range of product formats. These include pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter (‘OTC’) capsules, pills, tablets, and oral suspensions. The technology was specifically designed for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients…

Continue Reading

MondaySep 27, 2021 1:10 pm

HempNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Eyes Commercial Plans to Become B2B Wholesale Supplier of Rare Cannabinoids

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company based in British Columbia, Canada, is focused on advancing a pipeline of cannabinoid-based pharmaceutical drug candidates. The company is developing a proprietary cannabinoid synthesis manufacturing system known as IntegraSyn(TM), which is designed to advance rare and lesser-known cannabinoid production to commercial levels. A recent article discussing this quotes InMed CEO Eric A. Adams. “The next key milestone is to manufacture our first large-scale batch through a pharma-grade-ready process in the coming months. We will continue to optimize the process and scale up the IntegraSyn process into larger vessels,” Adams said in a recent…

Continue Reading

MondaySep 27, 2021 12:54 pm

HempNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Completes First Step in European Expansion Plan

Flora Growth Corp. (NASDAQ: FLGC) recently closed a €2 million investment in Hoshi International Inc., a fully integrated cannabis company, and uniquely positioned to become the leading provider of cannabis and derivative products for the budding European market. With the investment, Flora is set to capitalize on Hoshi’s strong European presence as well as leverage its technical know-how and understanding of its European market to not only expand its reach but also obtain its European Union Good Manufacturing Practices (“EU-GMP”) certification. A recent article reads, “Flora hopes to capitalize on Hoshi’s understanding of and presence within the European market to…

Continue Reading

FridaySep 24, 2021 2:14 pm

HempNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enhancing Performance of Antiviral Drugs, CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX) is making significant progress in advancing its patented DehydraTECH(TM) drug delivery technology. Lexaria recently reviewed its successful 2021 antiviral drug program. “The company has progressed significantly in evidencing that DehydraTECH can sufficiently enhance the usable fraction of known antiviral drugs that reach the bloodstream to safely and more effectively do what they are designed to accomplish,” reads a recent article. In addition to the antiviral program, Lexaria is also focused on another applied R&D program — hypertension. On July 29, it released partial results from a human clinical study, HYPER-H21-1, evaluating DehydraTECH-processed cannabidiol (“CBD”) for…

Continue Reading